APYX Insider Trading Activity and SEC Form 4 Filings
APYX insider trading summary
No open-market insider purchases or sales of Apyx Medical Corp (APYX) have been reported on SEC Form 4 in the past 12 months.
Latest APYX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 13, 2024 | Matthew C Hill | Chief Financial Officer | Buy | $6K (5,336 @ $1.13) |
| Dec 12, 2023 | Matthew C Hill | Chief Financial Officer | Buy | $5K (2,500 @ $2.19) |
| Nov 14, 2023 | Charles D. Goodwin II | Chief Executive Officer | Buy | $79K (50,000 @ $1.57) |
| Jun 26, 2023 | Todd Hornsby | Executive Vice President | Sell | $113K (15,000 @ $7.56) |
| Aug 29, 2022 | Charles D. Goodwin II | Chief Executive Officer | Buy | $58K (9,750 @ $5.97) |
| Aug 29, 2022 | Charles D. Goodwin II | Chief Executive Officer | Buy | $12K (2,000 @ $5.93) |
| May 13, 2020 | Charles D. Goodwin II | Chief Executive Officer | Buy | $93K (28,250 @ $3.30) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.